Table 10 Risk stratifications for each AJCC substage in training and test cohorts
From: Nomograms to predict survival after colorectal cancer resection without preoperative therapy
| Â | Â | Training cohort | Â | Test cohort | ||||
|---|---|---|---|---|---|---|---|---|
AJCC stages | Cut-off Points | Cumulative Survival, 60Â months, % | HR | 95Â % CI | Pairwise Plog-rank | HR | 95Â % CI | Pairwise Plog-rank |
Cancer-specific survival | ||||||||
 Stage I | ||||||||
  Low risk group (L) | ≤70.0 | 97.7 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0205 |
  Median risk group (M) | ≤97.2 | 94.4 | 2.44 | 1.91–3.13 | L v H < 0.0001 | 1.75 | 1.24–2.45 | L v H < 0.0001 |
  High risk group (H) | 97.2+ | 88.4 | 4.73 | 3.66–6.12 | M v H < 0.0001 | 6.12 | 4.27–8.77 | M v H < 0.0001 |
 Stage IIA | ||||||||
  Low risk group (L) | ≤122.7 | 93.9 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤149.4 | 87.7 | 1.90 | 1.64–2.19 | L v H < 0.0001 | 2.11 | 1.4–2.58 | L v H < 0.0001 |
  High risk group (H) | 149.4+ | 76.2 | 3.96 | 3.41–4.61 | M v H < 0.0001 | 4.66 | 3.80–5.72 | M v H < 0.0001 |
 Stage IIB | ||||||||
  Low risk group (L) | ≤151.2 | 84.4 | ref |  | L v M = 0.0046 | ref |  | L v M = 0.0220 |
  Median risk group (M) | ≤178.4 | 71.1 | 1.84 | 1.28–2.64 | L v H < 0.0001 | 2.09 | 1.29–3.39 | L v H < 0.0001 |
  High risk group (H) | 178.4+ | 54.1 | 3.30 | 2.22–4.90 | M v H < 0.0012 | 5.27 | 3.16–8.81 | M v H < 0.0001 |
 Stage IIC | ||||||||
  Low risk group (L) | ≤158.0 | 76.7 | ref |  | L v M = 0.0121 | ref |  | L v M = 0.6571 |
  Median risk group (M) | ≤181.8 | 62.3 | 1.64 | 1.16–2.31 | L v H < 0.0001 | 1.12 | 0.72–1.74 | L v H < 0.0001 |
  High risk group (H) | 181.8+ | 45.6 | 2.79 | 1.93–2.03 | M v H < 0.0020 | 2.73 | 1.68–4.42 | M v H < 0.0001 |
 Stage IIIA | ||||||||
  Low risk group (L) | ≤88.9 | 94.8 | ref |  | L v M = 0.0116 | ref |  | L v M < 0.0210 |
  Median risk group (M) | ≤120.2 | 91.6 | 2.04 | 1.39–2.99 | L v H < 0.0001 | 2.51 | 1.36–4.63 | L v H < 0.0001 |
  High risk group (H) | 120.2+ | 75.6 | 6.84 | 4.57–10.24 | M v H < 0.0001 | 6.54 | 3.20–13.35 | M v H = 0.0015 |
 Stage IIIB | ||||||||
  Low risk group (L) | ≤147.6 | 85.9 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤180.3 | 72.1 | 2.09 | 1.89–2.32 | L v H < 0.0001 | 2.35 | 2.04–2.70 | L v H < 0.0001 |
  High risk group (H) | 180.3+ | 50.1 | 4.25 | 3.80–4.76 | M v H < 0.0001 | 5.34 | 4.55–2.67 | M v H < 0.0001 |
 Stage IIIC | ||||||||
  Low risk group (L) | ≤187.2 | 65.1 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤218.0 | 41.6 | 1.99 | 1.74–2.27 | L v H < 0.0001 | 2.01 | 1.72–2.36 | L v H < 0.0001 |
  High risk group (H) | 218.0+ | 24.8 | 3.49 | 3.01–4.04 | M v H < 0.0001 | 4.05 | 3.39–4.84 | M v H < 0.0001 |
 Stage IV | ||||||||
  Low risk group (L) | ≤255.6 | 26.2 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤292.1 | 12.0 | 1.56 | 1.46–1.67 | L v H < 0.0001 | 1.85 | 1.70–2.01 | L v H < 0.0001 |
  High risk group (H) | 292.1+ | 4.0 | 2.78 | 2.57–3.01 | M v H < 0.0001 | 3.34 | 3.20–3.70 | M v H < 0.0001 |
Overall survival | ||||||||
 Stage I | ||||||||
  Low risk group (L) | ≤55.1 | 94.6 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤79.9 | 84.5 | 2.94 | 2.58–3.35 | L v H < 0.0001 | 3.10 | 2.58–3.72 | L v H < 0.0001 |
  High risk group (H) | 79.9+ | 63.1 | 9.07 | 7.90–10.41 | M v H < 0.0001 | 10.70 | 8.80–13.01 | M v H < 0.0001 |
 Stage IIA | ||||||||
  Low risk group (L) | ≤75.9 | 90.6 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤101.4 | 77.0 | 2.66 | 2.42–2.91 | L v H < 0.0001 | 2.86 | 2.50–3.28 | L v H < 0.0001 |
  High risk group (H) | 101.4+ | 49.1 | 7.38 | 6.68–8.15 | M v H < 0.0001 | 7.80 | 6.77–8.97 | M v H < 0.0001 |
 Stage IIB | ||||||||
  Low risk group (L) | ≤93.5 | 80.3 | ref |  | L v M = 0.0007 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤120.4 | 64.7 | 1.86 | 1.40–2.45 | L v H < 0.0001 | 3.86 | 2.60–5.72 | L v H < 0.0001 |
  High risk group (H) | 120.4+ | 26.8 | 5.48 | 4.00–7.49 | M v H < 0.0001 | 8.03 | 5.27–12.22 | M v H < 0.0001 |
 Stage IIC | ||||||||
  Low risk group (L) | ≤96.9 | 73.6 | ref |  | L v M < 0.0001 | ref |  | L v M = 0.2111 |
  Median risk group (M) | ≤121.9 | 54.4 | 2.09 | 1.56–2.80 | L v H < 0.0001 | 1.35 | 0.92–1.98 | L v H < 0.0001 |
  High risk group (H) | 121.9+ | 35.5 | 3.54 | 2.58–4.86 | M v H = 0.0002 | 3.81 | 2.46–5.91 | M v H < 0.0001 |
 Stage IIIA | ||||||||
  Low risk group (L) | ≤60.0 | 94.6 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0316 |
  Median risk group (M) | ≤90.4 | 84.3 | 3.67 | 2.76–4.87 | L v H < 0.0001 | 2.10 | 1.36–3.25 | L v H < 0.0001 |
  High risk group (H) | 90.4+ | 59.4 | 11.71 | 8.66–15.84 | M v H < 0.0001 | 9.07 | 5.70–14.45 | M v H < 0.0001 |
 Stage IIIB | ||||||||
  Low risk group (L) | ≤91.0 | 82.3 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤116.9 | 63.7 | 2.28 | 2.09–2.48 | L v H < 0.0001 | 2.72 | 2.42–3.07 | L v H < 0.0001 |
  High risk group (H) | 116.9+ | 36.6 | 5.06 | 4.60–5.56 | M v H < 0.0001 | 6.55 | 5.75–7.47 | M v H < 0.0001 |
 Stage IIIC | ||||||||
  Low risk group (L) | ≤110.6 | 63.3 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤137.0 | 35.7 | 2.10 | 1.86–2.37 | L v H < 0.0001 | 1.94 | 1.68–2.24 | L v H < 0.0001 |
  High risk group (H) | 137.0+ | 18.2 | 3.97 | 3.47–4.55 | M v H < 0.0001 | 4.33 | 3.68–5.11 | M v H < 0.0001 |
 Stage IV | ||||||||
  Low risk group (L) | ≤157.2 | 24.2 | ref |  | L v M < 0.0001 | ref |  | L v M < 0.0001 |
  Median risk group (M) | ≤183.3 | 9.9 | 1.59 | 1.49–1.69 | L v H < 0.0001 | 1.87 | 1.73–2.03 | L v H < 0.0001 |
  High risk group (H) | 183.3+ | 3.0 | 2.79 | 2.58–3.01 | M v H < 0.0001 | 3.51 | 3.19–3.88 | M v H < 0.0001 |